Where I see patients (1)
My reviews
Selected research
-
Correction: The Evolution of Anti‑CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.
CNS drugs
-
The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.
CNS drugs
-
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
The Lancet. Neurology
4.9